Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: Gilead Sciences
Yahoo Beta:1.26

Company Description:  Gilead discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific.

Purchase Date:26 Feb 2014 Sale Date:02 Oct 2019
Purchase Price:$84.22 Sale Price:$61.80
  --Split Adjusted:$84.22  --Split Adjusted:$61.80
Shares Purchased:100 Shares Sold:25
  --Split Adjusted:100  --Split Adjusted:25
Transaction Fee:$9.99 Transaction Fee:$2.35
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$83.95 High$0.00
Date25 Feb 2014 Date01 Jan 1996
Low$58.74 Low$0.00
Date27 Aug 2013 Date01 Jan 1996
S&P (Purchase Date):$1,859.45 S&P (Sale Date):$2,887.61

Timing:  We bought near the six month high.
Reason:  The company is well-positioned in a growing segment of the industry and its new HIV medications will be more successful than the market currently believes.

Timing:  x
Reason:  Truvada, which represents one sixth of Gilead's revenue, will go off patent next year. Gilead has had negative cash flows in two of the last three years, but has had positive earnings surprises the last two quarters, making this an attractive time to exit.

S&P Gain: 55.29 % Annualized Gain: 8.31%
Stock Gain: -26.62 % Annualized Gain: -5.46%

Net Holding Return ($): $-314.84
Net Holding Return (%): -14.88 %